Tim Gunn

• Health & Medicine

Olaparib approved for 800 prostate and breast cancer patients in England

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

11 April 2023

• Health & Medicine

Children’s cancer charities team up for tomorrow’s treatments

We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people. We're helping treble funding for paediatric Experimental Cancer Medicine Centres, paving the way to more effective and less toxic treatments for children and young people.

3 April 2023

• Charity News

Cancer Research UK appoints new Trustees and independent Committee Members

Cancer Research UK today announced the appointments of Rakshit Kapoor and Hitesh Thakrar to its Council of Trustees, the charity’s board of directors. Cancer Research UK today announced the appointments of Rakshit Kapoor and Hitesh Thakrar to its Council of Trustees, the charity’s board of directors.

16 March 2023

• Health & Medicine
• Science & Technology

Time to take on 9 new Cancer Grand Challenges

These are some of the biggest questions in cancer research. Cancer Grand Challenges are looking for research teams that can help answer them. These are some of the biggest questions in cancer research. Cancer Grand Challenges are looking for research teams that can help answer them.

8 March 2023

• Science & Technology

Can cancer cells communicate?

Cancer cells use electricity to help them spread. A new study shows it might be key to controlling their other behaviours, too. Cancer cells use electricity to help them spread. A new study shows it might be key to controlling their other behaviours, too.

28 February 2023

• Science & Technology

The ecDNA story – catching the mastermind behind cancer evolution

Aggressive cancers use ecDNA to evolve quickly and resist treatment. This is how we found that out, and how we're going to stop it. Aggressive cancers use ecDNA to evolve quickly and resist treatment. This is how we found that out, and how we're going to stop it.

20 February 2023

• Health & Medicine

Better together: improving brain tumour treatment

We've helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective. We've helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective.

13 February 2023

• Health & Medicine

Early-onset cancer: why are more young adults being diagnosed?

Cancer rates in adults under 50 have been rising since the 1990s. Our researchers are leading the effort to turn the trend around. Cancer rates in adults under 50 have been rising since the 1990s. Our researchers are leading the effort to turn the trend around.

24 January 2023

• Health & Medicine

Chemo before surgery helps stop colon cancer coming back

Giving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to a trial we funded. Giving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to a trial we funded.

20 January 2023

• Health & Medicine
• Science & Technology

Our most important cancer research stories of 2022

This year has been full of research, advances and people worth celebrating. Here are some of our biggest stories from the past 12 months.  This year has been full of research, advances and people worth celebrating. Here are some of our biggest stories from the past 12 months. 

14 December 2022

• Health & Medicine

NICE recommends pembrolizumab for 1,600 more people with breast cancer

The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales. The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

14 November 2022

• Science & Technology

The Nobel Prize winner helping us treat children's cancers

Professor Carolyn Bertozzi won the 2022 Nobel Prize in Chemistry. She's using all she's learned to create better treatments for solid tumours in children. Professor Carolyn Bertozzi won the 2022 Nobel Prize in Chemistry. She's using all she's learned to create better treatments for solid tumours in children.

8 November 2022